English
75183
|
Shenzhen Beimei Pharmaceutical Co., Ltd. ("Beimei Pharmaceutical") announced that on May 15, 2024, Beimei Pharmaceutical and Sol-Gel Technologies, Ltd. ("Sol-Gel", Nasdaq: SLGL) enters into an asset purchase agreement (the "Agreement") to acquire the acne drug TWYNEO from Sol-Gel®Related assets in China (including Hong Kong, Macau, and Taiwan) and Israel (the "Area"). According to the agreement, Beimei Pharmaceutical obtained TWYNEO®Related assets in the region include but are not limited to patents, trademarks and domain names related to product development, commercialization and production.  Ms. Wu Guangmei, founder and CEO of Beimei Pharmaceutical, said: "There are long-term unmet clinical needs in China's acne market, especially for adolescents. TWYNEO®As a new acne compound drug approved by the US FDA in recent years, its efficacy has been clinically proven. Beimei Pharmaceutical will launch TWYNEO ®The registration and commercialization process in the above areas will bring new treatment methods to the majority of acne patients. I believe that through this transaction, Beimed Pharmaceuticals will further deepen its pediatric product layout in the field of dermatology, and the development of Beimed Pharmaceuticals will also enter a new stage. ” Alon Seri-Levy, CEO of Sol-Gel, said: “This agreement is a testament to TWYNEO’s®With potential outside of the U.S. market, we look forward to announcing FDA approval of TWYNEO assets®More commercial collaborations in other regions. ” About TWYNEO® TWYNEO®It is the first and only FDA-approved topical cream consisting of a fixed-dose combination of tretinoin and benzoyl peroxide for the treatment of acne vulgaris in children and adult patients nine years of age and older. As the first-line treatment for acne vulgaris, benzoyl peroxide and tretinoin are one of the classic combination treatments recommended by domestic and foreign guidelines. However, the two ingredients are prone to chemical reactions and cannot be combined. They need to be used at different times. Factors such as skin irritation of external benzoyl peroxide or tretinoin alone affect patient compliance. TWYNEO ®For the first time, the breakthrough use of patented microencapsulation technology solves the difficulty of combining the two ingredients benzoyl peroxide and retinoic acid, achieving a historic combination of medications. At the same time, the microencapsulation technology also alleviates the skin irritation reaction of topical benzoyl peroxide or retinoic acid. TWYNEO ®It has been proven in clinical trials that it can significantly reduce inflammatory and non-inflammatory acne lesions in patients by more than 60%. After the patient receives a course of treatment, the clinical indicators (IGA) have improved by more than 2 levels and achieved complete or almost complete clearance. TWYNEO ®Safe and effective, it greatly improves patient compliance and reduces side effects such as skin irritation.(Refer to TWYNEO®FDA approved instructions) TWYNEO®Exclusively licensed to Galderma for commercialization in the United States and approved for marketing in July 2021； Exclusively licensed to Searchlight in Canada. About acne vulgaris Acne vulgaris is a chronic inflammatory disease of the sebaceous glands produced by the adolescent Corynebacterium acnes under the influence of normal circulating dehydroepiandrosterone. The number of acne patients in China is huge. According to cross-sectional statistics of the Chinese population, the incidence rate of acne is 8.1%, and more than 95% of people will have varying degrees of acne. The peak incidence of acne is in adolescence, with the prevalence rate reaching more than 80% among teenagers aged 11-25 years old and about 15% among young people aged 25-35 years old. Research shows that in the past 20 years, the incidence of acne in China has increased significantly, with a growth rate of about 36%. The growth trend far exceeds the global average, and among patients under the age of 20, the acne recurrence rate is as high as 37.3%. ( 数据来源Prevalence of Acne Vulgaris in Chinese Adolescents and Adults: A Community-based Study of 17,345 Subjects in Six Cities） Existing treatments for acne vulgaris include topical preparations such as retinoic acid, benzoyl peroxide and antibiotics, or oral antibiotics, isotretinoin, etc. Domestic and foreign guidelines have proposed that combination therapy can significantly increase drug efficacy, reduce adverse reactions, and increase patient compliance. At present, the Chinese market is still dominated by single-prescription preparations and there are few types of fixed-dose compound drugs. Existing acne drugs may affect patient compliance due to safety issues. Domestic treatment needs have not been fully met, and the market still has huge room for improvement. According to analysis by Global Market Insights, the global acne treatment drug market will grow from US$9.9 billion in 2022 to US$17.5 billion in 2032, with a CAGR of 5.86%. The global acne treatment drug market will expand steadily due to the increase in the penetration rate of new products. The domestic acne treatment market will grow from 4.2 billion yuan in 2024 to 8.1 billion yuan in 2027. ( Refer to Pacific Securities' April 2024 "Special Report on New Acne Drugs"） About Sol-Gel Technologies  Sol-Gel Technologies, Ltd. is a dermatology company focused on discovering, developing, commercializing or partnering on medicines to treat skin diseases. Sol-Gel developed TWYNEO ®(FDA-approved for the treatment of acne vulgaris in children and adult patients 9 years of age and older), and EPSOLAY®(Approved by the FDA for the treatment of inflammatory lesions of rosacea in adults). Both drugs are exclusively licensed to Galderma for commercialization in the United States ； and licensed exclusively to Searchlight in Canada. TWYNEO ®Beim Pharmaceutical purchased the exclusive commercialization rights in China (including Hong Kong, Macau, and Taiwan) and Israel. The company's pipeline also includes a Phase 3 clinical trial of orphan drug and breakthrough candidate SGT-610, a novel topical Hedgehog inhibitor being developed to prevent new basal cell carcinoma lesions in patients with Gorlin syndrome with an expected improved safety profile compared to oral Hedgehog inhibitors.； Additionally, the company is investigating SGT-210, a topical drug candidate for the treatment of a rare form of hyperkeratosis. For more information about Sol-Gel, please visit the Sol-Gel website: www.sol-gel.com About Beimei Pharmaceutical  Shenzhen Beimei Pharmaceutical Co., Ltd. (referred to as "Beimei Pharmaceutical") focuses on the field of children's prescription drugs, integrating the entire industry chain capabilities of "R&D, production, sales, and global cooperation". It takes the independent research and development of excellent pediatric products and the introduction of global cooperation as its key driving strategy. Relying on Beimei Pharmaceutical's Lianyungang production base, it meets the production and global supply of a variety of children's special pharmaceutical dosage forms, aiming to provide high-quality, full range of drugs for pediatric patients. Beimei Pharmaceutical has deployed more than 40 children's products and has approved 4 products for marketing. Many of these innovative pharmaceutical products have global rights and independent intellectual property rights. The current product pipeline covers dermatology, respiratory system, digestive system, anti-infection, nervous system, neonatal, genetic and endocrine system and other fields. Beimei Pharmaceutical has established long-term partnerships with a number of global large international pharmaceutical companies, such as Hetero, Cipla, Deva, Dr. Reddy's, LTS, MedPharma, Synthon, EMP, NTC, Syrimed, etc. Beimei Pharmaceutical has completed hundreds of millions of yuan in angel round, round A, round B/B+ and round C financing, and has been recognized by many well-known investment institutions including Yifeng Capital and industry parties. For more details about the company, please visit Beimeiyaoye’s website: https://www.beimeiyaoye.com/  Scan the QR code｜Follow us Copyright statement The copyright of some images, fonts, audio/videos of this public account belongs to the copyright owner. If the copyright owner believes that his work is not suitable for online browsing or should not be used for free, please contact us by email in time (email address: info@beimeipharma.com), and we will quickly take appropriate measures to avoid unnecessary economic losses to both parties. Disclaimer This article is provided for informational purposes only by medical and health professionals and company insiders. No express or implied warranty is provided as to the accuracy, reliability or completeness of the content contained therein. It is for reference only. This information is not in any way a substitute for professional medical guidance and should not be considered diagnostic and treatment advice. If such information is used for purposes other than understanding information, the platform and the author do not assume relevant responsibilities. |
|
|
|
|
|
